京都大学：在海外提供“临床IPS细胞”：韩国风险投资公司
京都大学 iPS 细胞研究基金会：
我们首次在海外提供临床 iPS 细胞。
临床 iPS 细胞：
它变成各种组织和细胞，用于研究疑难杂症的治疗方法。
除了拥有大量研究人员且装备精良的“京都大学iPS细胞研究基金会”之外，很难做到。
提供给韩国风险投资公司：
根据基金会的说法，它从未在海外提供过。
上个月，我们将它提供给了一家韩国风险投资公司。
韩国和日本宪法：
韩国人的细胞特性与日本人相似。
事实证明，移植时不太可能发生排斥反应。
山中社长：
我们希望继续这些努力用于临床应用。
新闻 | 关西广播
https://www.ktv.jp/news/articles/27d952d4_7d45_44bc_a247_9d4636d50c59.html
A Bridge from Japan to Korea:
CiRA Foundation’s First Provision of Clinical-Grade iPS Cell Stock
News | CiRA Foundation
Key Points
CiRA Foundation®(“CiRA_F” located in Kyoto, Japan) has provided the clinical-grade iPS cell stock (iPSC stock) to iPS Bio, Inc (“iPS Bio” located in Pangyo, Korea).
This is the first time
that CiRA_F has provided the clinical-grade iPSC stock to an overseas.iPS Bio plans to conduct clinical trials
using GMP-grade iPSC products for treating Huntington’s disease, stroke, Alzheimer’s disease, as well as immune-oncology diseases, in the next few years.
Based on this incredible collaboration with iPS Bio,
CiRA_F will make further efforts to manufacture high-quality iPSC stock
for regenerative medicine to meet global standards,and will continue to contribute to the practical application of iPS cell technology through providing the iPSC stock to global partners of CiRA_F such as iPS Bio.
To accomplish the ultimate goal of “providing the top iPS cell technologies at affordable prices,
“CiRA_F has been supplying iPSC stock, SOPs, and quality evaluation services for regenerative medicine.
CiRA_F is always open to collaborating with partners.
News | CiRA Foundation